@article{9405ca49fc044c77be8e6d13f0bf211c,
title = "Global Physiology and Pathophysiology of Cough: Part 2. Demographic and Clinical Considerations: CHEST Expert Panel Report",
abstract = "Background: Cough characteristics vary between patients, and this can impact clinical diagnosis and care. The purpose of part two of this state-of-the-art review is to update the American College of Chest Physicians (CHEST) 2006 guideline on global physiology and pathophysiology of cough. Study Design and Methods: A review of the literature was conducted using PubMed and MEDLINE databases from 1951 to 2019 using prespecified search terms. Results: We describe the demographics of typical patients with cough in the clinical setting, including how cough characteristics change across age. We summarize the effect of common clinical conditions impacting cough mechanics and the physical properties of mucus on airway clearance. Interpretation: This is the second of a two-part update to the 2006 CHEST cough guideline; it complements part one on basic phenomenology of cough by providing an extended clinical picture of cough along with the factors that alter cough mechanics and efficiency in patients. A greater understanding of the physiology and pathophysiology of cough will improve clinical management.",
keywords = "airway clearance, cough, demographics, mucus, pathophysiology, physiology",
author = "{CHEST Expert Cough Panel} and Lorcan McGarvey and Rubin, {Bruce K.} and Satoru Ebihara and Karen Hegland and Alycia Rivet and Irwin, {Richard S.} and Bolser, {Donald C.} and Chang, {Anne B.} and Gibson, {Peter G.} and Stuart Mazzone",
note = "Financial/nonfinancial disclosures: The authors have reported to CHEST the following: S. B. M. declares personal fees from Merck and NeRRe Therapeutics and grant support from Merck, the Australian National Health and Medical Research Council, and the Australian Research Council. L. M. reports personal fees from Chiesi, GSK, Merck, NeRRe Therapeutics, and Shionogi Inc; grant support from Merck; and other support from AstraZeneca, Boehringer Ingelheim, and Chiesi. A. B. C. has received fees from Up to Date, is on the data safety monitoring board for a vaccine study (Glaxo), is an advisor for study design of an unlicensed product (Merck), and has received multiple peer reviewed competitive grants from the Australian National Health and Medical Research Council. B. K. R. has received consulting fees from Merck, Boehringer Ingelheim, GlycoMira, and Ionis and has research grants from the NIH and Cystic Fibrosis Foundation. Publisher Copyright: {\textcopyright} 2021 Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
month = oct,
doi = "10.1016/j.chest.2021.04.039",
language = "English",
volume = "160",
pages = "1413--1423",
journal = "Chest",
issn = "0012-3692",
publisher = "American College of Chest Physicians",
number = "4",
}